Dimebon latrepirdine: Completed Phase III enrollment

Medivation and Pfizer completed enrollment of 403 patients in the double-blind, placebo-controlled, international Phase III HORIZON trial evaluating 20 mg oral Dimebon given thrice daily for 6 months....